Showing results (141-150 of 203) with videos related to

Sort By:
Pageof 21
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|February 19, 2016
[Cost-effectiveness analysis of two breast cancer screening modalities in Shanghai, China]Miao Mo, Ying Zheng, Guangyu Liu, et al.
International Journal of Surgery (London, England)|November 13, 2025
A prospective single-center cohort study: integrating PET imaging and genomics to identify early biomarkers of response to dual-targeted PH neoadjuvant therapy in breast cancerBenlong Yang, Ming Chen, Panli Li, et al.
Breast Cancer Research and Treatment|June 22, 2020
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled studyBinghe Xu, Wei Li, Qingyuan Zhang, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 30, 2023
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in ChinaBinghe Xu, Huiping Li, Zefei Jiang, et al.
Molecular Therapy Oncolytics|December 2, 2021
Prognostic value of metabolic signature on 18F-FDGuptake in breast cancer patients after radiotherapyJin Meng, Emmanuel Deshayes, Li Zhang, et al.
Cell Death and Differentiation|January 28, 2021
Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the  receptor protein of CRL2<sup>Prame</sup> complexWenjuan Zhang, Lihui Li, Lili Cai, et al.
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer|May 16, 2024
Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine <i>vs.</i> lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapyXiaojia Wang, Wei Li, Yongmei Yin, et al.
Breast Cancer Research and Treatment|January 15, 2018
Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survivalYing Zhang, Yajie Ji, Jianwei Li, et al.
Cancer Chemotherapy and Pharmacology|December 16, 2019
Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancerLiang Huang, Xiaojia Wang, Liheng Zhou, et al.
International Journal of Surgery (London, England)|August 15, 2024
CXCR6 expression correlates with radiotherapy response and immune context in triple-negative breast cancer-experimental studiesJin Meng, Yilan Yang, Jiaojie Lv, et al.
Pageof 21